New Page 1
January
30, 2009
News Headlines
Elderly Glioblastoma Patients May Be
Undertreated Diet Modification
Slows PSA Doubling After Prostate Cancer Treatment Gene Variants Increase Risk of Alcohol-Related
Cancer Fluorouracil-based Adjuvant Therapy May Cure
Colon Cancer Cured Meats Tied to Childhood Leukemia Risk
Enhanced Patient Intervention
Increases Colorectal Screening Compliance Prostate Cancer May Cause Neglect of Other
Illness Childhood Cancer Survivors
Miss Needed Mammograms Risk Factors
Identified to Guide Preventive Mastectomy Decision High-Dose Epirubicin for Breast Cancer
Provides No Overall Benefit Chemotherapy Enhances Vaccine-Induced
Anti-Melanoma Immunity
Cancerpage news is updated daily, Monday
through Friday, and on the weekends as
warranted. More than 39 new
articles have been added to cancerpage news since the last newsletter.
To see ALL the latest stories, go to the
cancerpage.com search page and click on Submit (but
leave search field black.)
Putting TV Medical Drama to the Clinical Test
Nip/Tuck recently did a commendable job of shedding light on male breast
cancer. But in dramatizing the disease that kills an estimated 450
American men each year, it got some of the medicine wrong. LA
Times reporter Marc Siegel decontructed the episode recently,
here
in his column, The Unreal
World. This is a very interesting read.
Debate over Off-Label Use of Cancer Drugs
Medicare's decision to cover more off-label use of
cancer drugs has sparked some serious debate. You can read about it. Shorter verion here. Longer
version of the story is available on the NYTimes
site
here.
(Access requires a free subscription to the NYT online. You can use the
cancerpage login. User: cancerpage PW: visitor.) Cancerpage
ran a news story when Medicare made the announcement January 12th
here
.
'Seriously, This is Amazing..
...I'm
Brown!!!' --- That's what one of the posters exclaims on a discussion
board for people who use an UNAPPROVED product for skin tanning.
An injectible solution - Melanotan -
is sold on the internet as "synthetic versions of melanocyte stimulating
hormone that were created, synthesized and developed at The University of
Arizona and the Arizona Cancer Center". The health agencies of four
governments have warned
that Melanotan could be dangerous but apparently its popularity is growing. Now
a letter in the British Medical Journalreports on two patients who had "rapidly changing moles and
a conspicuous tan" when they showed up at the clinic. The moles, all benign,
changed after the self-administered injections. One of the moles was "severely
dysplastic." Read letter
here.
The melanotan discussion board can be found
here . FDA
Melanotan II warning dated 2007.
Value of Acupuncture in
Pain Relief Questioned
Large review of the research concludes the pain relief
from acupuncture is small and hard to tease out from the bias of testing. The
findings are published in the British Medical Journal:
"We found a small analgesic effect of acupuncture that seems to lack
clinical relevance and cannot be clearly distinguished from
bias. Whether needling at acupuncture points, or at anysite, reduces
pain independently of the psychological impactof the treatment ritual
is unclear." Read the
report here.
In the Clinic/In the
Lab
New research suggests the best time to get chemo is at
night, when cancer cells are less able to repair the damage done to their DNA.
That's the finding of work by Dr. Aziz Sancar of the University of North
Carolina's School of Medicine. He and his team were interested in investigating
how doctors could take advantage of the body's circadian rhythm.
Read
more about their work on how the time of day might affect the potency of
chemotherapy here.
Men who develop prostate cancer AND carry one
of two breast cancer gene mutations (BRCA1 and BRCA2) are more likely to have an
aggressive cancer. The presence of the gene mutation could provide the
patient and his physician a tool for guiding treatment decisions in an early
stage diagnosis, according
to researchers
at the Albert
Einstein College of Medicine of Yeshiva
University.
|